Disulfidptosis and Androgenic Cancers: From Molecular Mechanisms to Clinical Applications and Future Translational Research

Review surveys disulfidptosis — a newly described cell death mechanism — as a theoretical target in prostate, testicular, and bladder cancer; no original data

Journal: Frontiers in Endocrinology | Published: 2026-02-25 | Type: Review | PMID: 41821736 Authors: Wang Xueyang, Zhao Juan, Li Qiming, Chang Jiaqing, Zhao Weiwei, Xing Xiping (Gansu University of Chinese Medicine / Affiliated Hospital, Lanzhou, China) Funding/COI: Funding not disclosed. Authors declare no commercial or financial conflicts of interest.

Summary

Disulfidptosis is a form of programmed cell death discovered around 2023, triggered by excess intracellular disulfide bond formation under glucose starvation, causing cytoskeletal collapse. This narrative review argues that disulfidptosis could theoretically be exploited as a therapeutic target in prostate, testicular, and bladder cancers. The paper contains no original data — it synthesizes existing literature and speculates about future drug development and nanotechnology-based delivery systems.

Claims

• Disulfidptosis operates through dysregulation of protein disulfide bonds, distinct from apoptosis, ferroptosis, and other known cell death pathways
• Key regulatory genes in disulfidptosis (SLC7A11/xCT and associated GLUT1-dependent metabolic stress) are reportedly altered in urological cancers
• Nanotechnology-assisted targeted delivery is proposed as a strategy to improve specificity and reduce side effects of disulfidptosis-inducing agents
• The authors acknowledge "inadequate systematic research" on upstream/downstream signaling and "lack of highly specific and sensitive in vivo detection methods"
• No effect sizes, clinical trial data, or patient outcomes are reported anywhere in this paper

Study Quality

This is a narrative review with no original data, no systematic search methodology, no PRISMA flow, and no defined inclusion/exclusion criteria for papers cited. The authors' institution specializes in traditional Chinese medicine, which is a notable mismatch with the paper's subject matter of molecular oncology mechanisms — not necessarily disqualifying, but worth noting when evaluating depth of expertise. The paper was published in Frontiers in Endocrinology, a journal in the Frontiers family, which operates a peer review model that has faced sustained criticism for permitting lower methodological rigor than traditional journals.

The conclusion section is candid about the field's immaturity: current studies "focus on superficial phenomena," detection methods are lacking, and regulatory network models need to be "more refined." That candor is admirable, but it also describes a field where a review paper adds limited value over simply reading the handful of primary papers that exist.

Red Flags

• No original data; entirely speculative and synthesized
• Funding source undisclosed — for a review paper from a Chinese medicine university writing in molecular oncology, transparency matters
• Published in a Frontiers journal with known peer-review concerns
• Conflates "disulfidptosis" and "apoptosis" in places in the conclusion, suggesting imprecise handling of the mechanisms under review
• Uses language approaching "breakthrough" territory: "significant breakthrough in the treatment of urological cancers" appears in the conclusion, contrary to honest scientific communication
• Institutional affiliation (Chinese medicine university) creates questions about the authors' primary domain expertise relative to this topic
• No quantitative synthesis, no tables of evidence quality, no risk-of-bias assessment

Strengths

• Covers a genuinely new and potentially important cell death mechanism that is underrepresented in urological cancer literature
• The conclusion's self-criticism about methodological gaps in the field is unusually honest for a review paper
• Correctly identifies the tumor microenvironment and immune interaction as underexplored angles

Verdict

This is a speculative narrative review on a real but very early-stage biological concept — disulfidptosis was only characterized around 2023, and applying it to clinical oncology is still largely theoretical. The paper offers a readable orientation to the topic but adds no original analysis, no systematic evidence synthesis, and no data. The undisclosed funding, institutional mismatch, and Frontiers venue compound the concern. File this as background reading if you're tracking disulfidptosis as an emerging concept; don't cite it as evidence that the mechanism has clinical relevance in urological cancers, because that case hasn't been made here.